APA (7th ed.) Citation

Stacy Davis, Teresa Edwards, Lindsey Norcross, Sheri Fehnel, Amélie Beaudet, Marie Eckart, & John Fastenau. (2023). Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: Qualitative patient research findings in current and former users of oral selexipag. SpringerOpen.

Chicago Style (17th ed.) Citation

Stacy Davis, Teresa Edwards, Lindsey Norcross, Sheri Fehnel, Amélie Beaudet, Marie Eckart, and John Fastenau. Use of the National Cancer Institute Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events to Assess Treatment Tolerability in Pulmonary Arterial Hypertension: Qualitative Patient Research Findings in Current and Former Users of Oral Selexipag. SpringerOpen, 2023.

MLA (9th ed.) Citation

Stacy Davis, et al. Use of the National Cancer Institute Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events to Assess Treatment Tolerability in Pulmonary Arterial Hypertension: Qualitative Patient Research Findings in Current and Former Users of Oral Selexipag. SpringerOpen, 2023.